The Middle Eastern stock markets have recently shown resilience, with Dubai leading Gulf gains amid hopes for peace with Iran and Egypt achieving record highs. In this context, penny stocks—though an old term—remain relevant as they often represent smaller or newer companies that can offer growth potential at lower price points. By focusing on those with strong balance sheets and solid fundamentals, investors may uncover hidden gems in the market that provide both stability and potential upside.
Top 10 Penny Stocks In The Middle East
| Name |
Share Price |
Market Cap |
Financial Health Rating |
| Alpha Data PJSC (ADX:ALPHADATA) |
AED1.50 |
AED1.5B |
★★★★★☆ |
| Amanat Holdings PJSC (DFM:AMANAT) |
AED1.27 |
AED3.18B |
★★★★★☆ |
| Sharjah Insurance Company P.S.C (ADX:SICO) |
AED1.52 |
AED228M |
★★★★★★ |
| Al Wathba National Insurance Company PJSC (ADX:AWNIC) |
AED3.10 |
AED641.7M |
★★★★★★ |
| Dubai Investments PJSC (DFM:DIC) |
AED3.78 |
AED16.63B |
★★★★★☆ |
| Al Waha Capital PJSC (ADX:WAHA) |
AED1.87 |
AED3.54B |
★★★★★☆ |
| Union Properties (DFM:UPP) |
AED0.74 |
AED3.26B |
★★★★★☆ |
| Abu Dhabi National Hotels Company PJSC (ADX:ADNH) |
AED0.373 |
AED4.72B |
★★★★★★ |
| Sharjah Cement and Industrial Development (PJSC) (ADX:SCIDC) |
AED1.07 |
AED650.83M |
★★★★★☆ |
| Tgi Infrastructures (TASE:TGI) |
₪2.358 |
₪185.1M |
★★★★★★ |
Click here to see the full list of 73 stocks from our Middle Eastern Penny Stocks screener.
Let's explore several standout options from the results in the screener.
Abra Information Technologies
Simply Wall St Financial Health Rating:★★★★★☆
Overview:Abra Information Technologies Ltd. offers information technology solutions in Israel with a market cap of ₪421.15 million.
Operations:The company generates revenue from its Software Solutions and Services Segment, totaling ₪554.01 million.
Market Cap:₪421.15M
Abra Information Technologies Ltd., with a market cap of ₪421.15 million, has shown consistent revenue growth, reaching ₪554.01 million in the last year. Despite stable earnings per share and a seasoned board, its Return on Equity remains low at 4.3%. The company maintains strong liquidity, with short-term assets exceeding liabilities and cash surpassing total debt. However, recent negative earnings growth and declining profit margins present challenges. While trading below estimated fair value offers potential appeal to investors seeking undervalued opportunities in the sector, careful consideration of its financial stability and growth prospects is warranted given current volatility levels.
Cipia Vision
Simply Wall St Financial Health Rating:★★★★☆☆
Overview:Cipia Vision Ltd. specializes in creating embedded computer vision AI solutions for the global automotive industry and has a market cap of ₪28.09 million.
Operations:The company's revenue is derived entirely from its Software & Programming segment, amounting to $1.46 million.
Market Cap:₪28.09M
Cipia Vision Ltd., with a market cap of ₪28.09 million, operates in the automotive AI sector but faces financial challenges typical of penny stocks. The company reported sales of US$1.46 million for 2025, down from US$1.81 million the previous year, and a net loss reduction to US$2.89 million from US$8.02 million. Despite no long-term liabilities and experienced management, Cipia's cash runway is less than one year, raising concerns about sustainability as highlighted by auditor doubts regarding its going concern status. High share price volatility further complicates its investment appeal amidst ongoing profitability struggles and limited revenue growth prospects.
NRGene Technologies
Simply Wall St Financial Health Rating:★★★★★★
Overview:NRGene Technologies Ltd is a research and development company specializing in intellectual property-intensive technological products within the AgTech sector, with a market cap of ₪33.18 million.
Operations:The company's revenue is primarily generated from the provision of services, totaling $3.17 million.
Market Cap:₪33.18M
NRGene Technologies Ltd, with a market cap of ₪33.18 million, operates in the AgTech sector and reported sales of US$3.17 million for 2025, up from US$1.29 million the previous year, indicating revenue growth despite being unprofitable. The company has no debt and maintains a stable cash runway exceeding three years due to positive free cash flow. While its share price remains highly volatile and return on equity is negative at -35.3%, NRGene has experienced management and board teams, with short-term assets comfortably covering both short- and long-term liabilities, offering some financial stability amidst ongoing profitability challenges.
Summing It All Up
-
Reveal the 73 hidden gems among our Middle Eastern Penny Stocks screener with a single click here.
-
Interested In Other Possibilities? AI is about to change healthcare. These 121 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TASE:ABRA TASE:CPIA and TASE:NRGN.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
